Jay Pepose - 10 Jan 2023 Form 4 Insider Report for Ocuphire Pharma, Inc. (OCUP)

Role
Director
Signature
/s/ Emily J. Johns, by Power of Attorney
Issuer symbol
OCUP
Transactions as of
10 Jan 2023
Net transactions value
$0
Form type
4
Filing time
12 Jan 2023, 16:34:53 UTC
Previous filing
06 Jul 2022
Next filing
21 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUP Common Stock Award +13,013 +40% 45,907 11 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUP Stock Option (right to buy) Award $0 +33,291 $0.000000 33,291 10 Jan 2023 Common Stock 33,291 $3.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted shares of common stock in lieu of cash for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $3.07 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 11, 2023.
F2 The option will vest with respect to 8,322 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter.